Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn’s disease patients will have an additional option for induction of risankizumab which is already approved…
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
calendar_today
August 27, 2026
domain
abbvie